Supported by
Statins May Have Cancer Benefits
Statin drugs, commonly prescribed for heart health, may prolong survival in some cancer patients.
Cholesterol-lowering statin drugs don’t just lower the risk of heart attacks. They may also help some cancer patients live longer.
Researchers writing in the British Journal of Clinical Pharmacology tracked adherence to statins in more than 38,000 Australian women with newly diagnosed breast cancer, colorectal cancer or melanoma, three commonly diagnosed cancers. Average adherence to statins was 82 percent in the year preceding their diagnoses.
They found that each 10 percent increase in adherence in the year before a cancer diagnosis was associated with an 8 percent reduction in breast cancer and colorectal cancer mortality. There was a slight, but statistically insignificant, reduction in melanoma mortality.
The women were taking a wide variety of lipid-lowering medicines, but the most common was atorvastatin (brand name Lipitor), followed by simvastatin (Zocor) and rosuvastatin (Crestor).
The study adjusted for age, tumor cell type, use of chemotherapy, diabetes and many other variables. But the lead author, Jia-Li Feng of the Queensland Institute of Medical Research in Australia, said that there remains the possibility of a “healthy-user effect” — that is, that people who conscientiously adhere to statins may be healthier in general, and that this could affect cancer-specific survival.
Taking lipid-lowering medication as prescribed by a doctor, Dr. Feng said, may provide women a better chance of surviving these cancers. But she emphasized that this is an observational study that does not prove causation, and the results must be confirmed with clinical trials.
The Fight Against Breast Cancer
The U.S. Preventive Services Task Force has recommended all women start getting regular mammograms at age 40, instead of 50, the previous recommendation. Here’s what the new guidelines mean for you.
We asked doctors to weigh in on the new mammograms guidelines and how younger women can understand and mitigate their breast cancer risk.
Scientists have long known that dense breast tissue is linked to an increased risk of breast cancer. A recent study adds a new twist.
Advancements in artificial intelligence are beginning to deliver breakthroughs in breast cancer screening by detecting the signs that doctors miss.
Surgery to remove a tumor is considered a critically important step to fighting breast cancer. But a study suggests it may not always be necessary.
We asked Times readers to share insights from their experiences with breast cancer. Read their stories.
Advertisement